Corbus Pharmaceuticals Q2: CRB-701, CRB-913, CRB-601 data readouts in H2 2025.

• Corbus Pharmaceuticals reports Q2 2025 financial results • Phase 1/2 dose expansion data for CRB-701 to be presented at ESMO 2025 • Phase 1 study for obesity drug CRB-913 initiated • All three clinical programs on track for data readouts in H2 2025 • Company anticipates impactful second half of 2025 with data readouts for CRB-701, CRB-913, and CRB-601

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) has reported its Q2 2025 financial results, showcasing a net loss of $17.7 million and a cash position of $116.6 million, providing sufficient runway through Q2 2027 [1]. The company's CEO, Yuval Cohen, Ph.D., highlighted the potential for a transformative second half of 2025, with scheduled data readouts anticipated for all three clinical programs.

Key highlights from the report include:

- CRB-701 (Nectin-4 targeting ADC): Phase 1/2 dose expansion data will be presented at the European Society for Medical Oncology (ESMO) Congress in October 2025. This data, from over 100 participants with HNSCC, cervical, and urothelial cancers, will provide insights into the efficacy and safety of the drug [2].
- CRB-913 (obesity drug): The 7-day multiple ascending dose (MAD) portion of its Phase 1 study has been initiated, with no reported treatment-related neuropsychiatric events in the single ascending dose (SAD) phase. This milestone is significant as it addresses a critical safety concern for CB1 inverse agonists [1].
- CRB-601 (anti-αvβ8 integrin mAB): The company is progressing with dose escalation, with data expected in Q4 2025 [1].

The company's financial results indicate an increase in operating expenses to $19.2 million from $11.0 million in Q2 2024, primarily due to clinical development costs. Despite the net loss, Corbus maintains a strong cash position, which will fund operations through 2027, allowing sufficient time to reach multiple value-inflection points across its pipeline [1].

Corbus Pharmaceuticals is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. The company's pipeline includes CRB-701, CRB-601, and CRB-913, targeting solid tumors and obesity, respectively.

The second half of 2025 is shaping up to be impactful for Corbus, with scheduled data readouts anticipated for all three clinical programs. Investors and financial professionals should closely monitor these developments, as they have the potential to significantly impact the company's valuation and market position.

References:
[1] https://www.stocktitan.net/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-pmujisfw9o08.html
[2] https://finance.yahoo.com/news/corbus-pharmaceuticals-reports-second-quarter-120000587.html